04375nam a22005655i 4500001001800000003000900018005001700027007001500044008004100059020003700100024003500137050001200172072001600184072002300200072001500223245011400238250001800352264007500370300004200445336002600487337002600513338003600539347002400575490006100599505148200660520082302142650002102965650002502986650003103011650003003042650004003072650003003112650002103142650002503163650003503188650003003223650004603253700009503299700008803394710003403482773002603516776003603542776003603578776003603614830006803650856004603718912001403764912001403778999001703792978-3-031-52864-4DE-He21320251030111752.0cr nn 008mamaa240329s2024    sz |    s    |||| 0|eng d  a97830315286449978-3-031-52864-47 a10.1007/978-3-031-52864-42doi 4aRS1-441 7aMQP2bicssc 7aMED0720002bisacsh 7aMQP2thema10aDrug Delivery and Targetingh[electronic resource] /cedited by Monika Schäfer-Korting, Ulrich S. Schubert.  a1st ed. 2024. 1aCham :bSpringer International Publishing :bImprint: Springer,c2024.  aX, 411 p. 70 illus.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda1 aHandbook of Experimental Pharmacology,x1865-0325 ;v2840 aPart I. Nanoparticles and other Advanced Technologies -- Knowledge-based design of multi-functional polymer-based nanoparticles -- Stimuli-responsive non-viral nanoparticles for gene delivery -- Sustainability in drug and nano-particle processing -- Advanced formulation approaches for proteins -- Microneedles and polymer films – delivery of peptides, proteins and nucleic acids -- Advances in vaccine delivery enhancers – small molecules and nanomaterials -- Biodegradable long acting injectables: Platform technology and industrial challenges -- Part II. Visualization Technologies -- Visualization of Nano-carriers and Drugs in Cells and Tissue -- Characterization of drug delivery systems by transmission electron microscopy -- Part III. Target Specific Delivery -- Blood-brain barrier-crossing strategies for improved treatment of CNS disorders -- Interactions of nano-systems with immune cells and cancer cells – a roadmap to clinical use?- Progress in ocular drug delivery: challenges and constraints -- New therapeutic options in pulmonal diseases – sphingolipids and sphingolipid metabolism -- Molecular therapeutics for pulmonary diseases – the need for drug targeting -- Delivery of mitochondrial RNA -- Part IV. Concerted Actions – Thinking the Drug from the Beginning -- ATMP formulations and delivery -- Preclinical testing and approval of ATMP -- Looking to the future – drug delivery in the prophylaxis and therapy of severe and chronic diseases.  aSince the publication of the Handbook of Experimental Pharmacology Vol. 197 in 2010 there have been important advances in drug development, drug delivery and – more recently – drug targeting. This is in particular relevant with the new generation of drugs acting on the immune system and tumors. These are quite often accompanied by major adverse reactions. Safe therapy is, therefore, an important area of research, in particular in chronic diseases and in persons of old age. In addition, the Covid-19 pandemic has brought renewed attention to vaccinations against viral infections, and mRNA vaccines have been tested for vaccination in tumor therapy, too. Vaccine delivery has stimulated important research on carriers which may pave the way for other applications and enhance a path to e.g. CRISPR-cas therapy. 0aPharmacy.964666 0aPharmacology.967844 0aMedicinexResearch.962598 0aBiologyxResearch.965629 0aClinical medicinexResearch.974123 0aPharmacovigilance.97427514aPharmacy.96466624aPharmacology.96784424aTranslational Research.97070424aClinical Research.97412424aDrug Safety and Pharmacovigilance.9742761 aSchäfer-Korting, Monika.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9742771 aSchubert, Ulrich S.eeditor.4edt4http://id.loc.gov/vocabulary/relators/edt9742782 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303152863708iPrinted edition:z978303152865108iPrinted edition:z9783031528668 0aHandbook of Experimental Pharmacology,x1865-0325 ;v28496924240uhttps://doi.org/10.1007/978-3-031-52864-4  aZDB-2-SBL  aZDB-2-SXB  c58766d58766